Datavant & Boehringer Ingelheim Expand RWE Partnership for 75+ Clinical Trials

What You Should Know:

–  Datavant, a leading health data platform, has announced an expanded collaboration with Boehringer Ingelheim to strengthen the pharmaceutical company’s real-world evidence (RWE) capabilities.

–  This partnership aims to advance clinical development and commercial strategy across 75 additional clinical trials and multiple new molecular entities (NMEs), leveraging Datavant’s cutting-edge privacy-preserving tokenization and data connectivity technologies.

Datavant and Boehringer Ingelheim Expand Partnership to Advance Scalable Real-World Evidence Ecosystem

The expanded collaboration highlights the growing importance of secure, connected data in transforming patient care. By utilizing Datavant Connect powered by AWS Clean Rooms, Boehringer Ingelheim will:

• Efficiently explore and assess third-party data sources without transferring or sharing underlying data
• Streamline data discovery, transformation, and linkage within its secure research environment
• Enhance insights across the patient journey, from clinical development to post-launch performance

Arnaub Chatterjee, President and GM of Life Sciences, Ecosystem, and Public Sector at Datavant, noted:
“We are honored to support Boehringer Ingelheim in revolutionizing patient care through a pioneering data strategy. By enabling secure and efficient data linkage at scale, Boehringer Ingelheim is setting a new benchmark for medical research and demonstrating how technology can reshape healthcare and improve outcomes.”

Boehringer Ingelheim’s Executive Director and Head of the Real World Evidence Analytics Center of Excellence, Paul Petraro, underscored the strategic importance of the partnership:
“Our investment in real-world data reflects Boehringer Ingelheim’s commitment to advancing medical research with cutting-edge technologies. By expanding this approach across more trials and launches, we aim to drive more personalized, cost-effective treatments that transform patient care.”

To integrate seamlessly with Boehringer Ingelheim’s research infrastructure, the teams will implement tokenization through a phased rollout. Key goals of the initiative include:

• Establishing a robust framework to guide future studies
• Demonstrating value to industry peers considering cloud-based tokenization and real-world evidence strategies